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BaCKgRoUND aND aIMS: Despite the availability of 
new-generation drugs, hepatocellular carcinoma (HCC) is still 
the third most frequent cause of cancer-related deaths world-
wide. Cerium oxide nanoparticles (CeO2NPs) have emerged 
as an antioxidant agent in experimental liver disease because 
of their antioxidant, anti-inflammatory, and antisteatotic prop-
erties. In the present study, we aimed to elucidate the poten-
tial of CeO2NPs as therapeutic agents in HCC.
appRoaCH aND ReSUltS: HCC was induced in 110 
Wistar rats by intraperitoneal administration of diethylni-
trosamine for 16  weeks. Animals were treated with vehicle 
or CeO2NPs at weeks 16 and 17. At the eighteenth week, 
nanoceria biodistribution was assessed by mass spectrometry 
(MS). The effect of CeO2NPs on tumor progression and 
animal survival was investigated. Hepatic tissue MS-based 
phosphoproteomics as well as analysis of principal lipid com-
ponents were performed. The intracellular uptake of CeO2NPs 
by human ex vivo perfused livers and human hepatocytes was 
analyzed. Nanoceria was mainly accumulated in the liver, 
where it reduced macrophage infiltration and inflammatory 
gene expression. Nanoceria treatment increased liver apoptotic 
activity, while proliferation was attenuated. Phosphoproteomic 
analysis revealed that CeO2NPs affected the phosphorylation 
of proteins mainly related to cell adhesion and RNA splicing. 
CeO2NPs decreased phosphatidylcholine-derived arachidonic 
acid and reverted the HCC-induced increase of linoleic acid 
in several lipid components. Furthermore, CeO2NPs reduced 
serum alpha-protein levels and improved the survival of HCC 
rats. Nanoceria uptake by ex vivo perfused human livers and 
in vitro human hepatocytes was also demonstrated.
CoNClUSIoNS: These data indicate that CeO2NPs par-
tially revert the cellular mechanisms involved in tumor pro-
gression and significantly increase survival in HCC rats, 
suggesting that they could be effective in patients with HCC. 
(Hepatology 2020;72:1267-1282).
Hepatocellular carcinoma (HCC) is the third leading cause of death by cancer worldwide.(1) HCC commonly arises in patients with 
underlying chronic liver disease and is considered a typ-
ical inflammation-associated tumor.(2) The appearance 
of cirrhosis greatly favors the onset of HCC through 
mechanisms not yet well known that began to be elu-
cidated in recent years.(3) In the last decade, complex 
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genetic alterations, epigenetic chromosomal aberrations, 
and cellular signaling pathways triggering tumor devel-
opment, progression, and metastasis have been charac-
terized.(4) The current systemic treatments of HCC are 
based on molecularly targeted therapies. Sorafenib, a 
multikinase inhibitor, was the first compound for first-
line treatment of patients with advanced-stage HCC.(5) 
However, clinical trials have found only modest 
improvement in overall survival,(6) and the emergence 
of resistance episodes reveals the need to develop effec-
tive therapies for HCC.(7) Although the available drugs 
improve clinical outcomes, the median overall survival 
continues to be approximately 1 year.(8,9)
Of particular importance is the role of reactive 
oxygen species (ROS) in the onset and progression 
of HCC.(10) Mechanistic studies show that ROS 
induce alterations in DNA and modify key cellular 
processes such as cell proliferation and apoptosis.(11) 
Thus, it has been hypothesized that HCC develops 
because chronic oxidative stress exerts a selective pres-
sure that favors the outgrowth of cells from progenitor 
clones that are more resistant to oxidative damage.(12) 
Antioxidant agents have demonstrated their efficacy 
in chronic liver diseases equilibrating hepatic ROS 
metabolism, thereby improving liver functionality.(13)
Recently, cerium oxide nanoparticles (CeO2NPs) 
have emerged as an antioxidant and anti-inflammatory 
agent. Superoxide dismutase activity(14) (conversion of 
superoxide anion into hydrogen peroxide and finally 
oxygen), catalase activity(15,16) (hydrogen peroxide into 
oxygen and water), and peroxidase activity(17) (hydro-
gen peroxide into hydroxyl radicals), among others, 
have been attributed to CeO2NPs. Consequently, 
the wide spectrum of antioxidant enzyme-mimetic 
activities of CeO2NPs has been explored in the treat-
ment of many diseases related to the overproduction 
of ROS. Thus, the ability of CeO2NPs to modu-
late oxidative stress in diseases ranging from retinal 
degeneration,(18) neurodegenerative diseases,(19) dia-
betes,(20) ischemia,(21) cardiopathies,(22) gastrointesti-
nal inflammation,(23) and especially cancer has been 
described.(24-27) As well, the therapeutic possibilities 
of CeO2NPs have been shown in the case of exper-
imental liver disease.(28-32)
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We considered the potential therapeutic value 
of CeO2NPs in an experimental model of HCC in 
rats by chronic administration of diethylnitrosamine 
(DEN). We assessed the impact of CeO2NPs on 
tumor progression and survival, the accumulation in 
isolated human liver, and their intracellular adsorption 
by human liver-derived cancer cells.
Material and Methods
SyNtHeSIS aND 
CHaRaCteRIZatIoN oF Rat 
SeRUM alBUMIN StaBIlIZeD 
Ceo2Nps
CeO2NPs of 4-5 nm were synthesized by the chem-
ical precipitation of cerium (III) nitrate hexahydrate 
(Sigma-Aldrich, St. Louis, MO) in a basic aqueous 
solution.(14,15,17,28) Cerium (III), 10 mM, was dissolved 
in 100  mL of Milli-Q water at room temperature. 
To this, 3  mL of tetramethylammonium hydroxide 
(TMAOH) solution (1 M) was added slowly at room 
temperature under vigorous stirring (final concentra-
tion of 10 mM), and the mixture was allowed to age 
under mild stirring overnight. During the first minutes, 
the solution is colorless, and then it turns progressively 
brownish. Afterward, nanoparticles (NPs) were puri-
fied by centrifugation (10,000g, 10  minutes, at room 
temperature), and the resultant pellet was resuspended 
in 100 mL aqueous solution of 1 mM TMAOH. The 
xylenol orange test and inductively coupled plasma–
mass spectrometry (ICP-MS) indicated a full con-
version of Ce to CeO2NPs. Thus, the final CeO2 
concentration for this synthesis was determined to be 
1.72  mg/mL (6.7•1015 NPs/mL) and then diluted to 
the 1  mg/mL employed solution. Further details on 
CeO2NPs synthesis and characterization can be found 
in the Supporting Information.
Ceo2Nps aDMINIStRatIoN
CeO2NPs or vehicle were dispersed in saline solu-
tion and intravenously given as a bolus (500  µL) 
through the tail vein. CeO2NPs (0.1  mg/kg body 
weight) or vehicle (saline solution containing 
TMAOH ammonium salts 0.8  mM) were injected 
twice a week for 2 consecutive weeks starting at the 
sixteenth week after beginning DEN administration.
HCC INDUCtIoN IN RatS
Experimental studies were performed in 118 male 
Wistar rats weighing 200  g (Charles-River, Saint 
Aubin les Elseuf, France). HCC was chemically 
induced in 110 rats by an intraperitoneal administra-
tion of DEN (50 mg/kg body weight; Sigma-Aldrich) 
once a week for 16 weeks, and eight healthy rats were 
included as a control group.
aCCUMUlatIoN oF Ce IN 
ISolateD HUMaN lIVeRS
To assess whether the human liver parallels the kinetic 
adsorption pattern shown by CeO2NPs in the rat liver, 
human livers from three donors, designated subjects 
H1, H2, and H3, were used in the present study. Livers 
were procured in the Hospital Clinic (Barcelona, Spain), 
rejected for transplantation, and approved for research.
Ceo2Nps aDSoRptIoN By HUMaN 
HepatoCyte CaNCeR CellS
To investigate whether human hepatocytes are able 
to intracellularly take up CeO2NPs, subsequent stud-
ies were performed in HepG2 cells, a human cell line 
derived from a liver HCC (ATCC, Manassas, VA).
etHICal appRoVal
The study was approved and performed according to 
the criteria of the Investigation and Ethics Committee 
of the Hospital Clínic Universitari (Barcelona, Spain). 
Animals received humane care according to the cri-
teria outlined in the “Guide for the Care and Use of 
Laboratory Animals”. The study of the human livers was 
conducted in the Hospital Clínic de Barcelona, which 
is part of the European Union–funded Consortium for 
Organ Preservation in Europe (http://www.ope-eu.com).




A description of the characterization of the 
CeO2NPs used in this study has been published.
(32) 
High-resolution transmission electron microscopic 
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(TEM) analysis indicated that the NPs had a spherical 
morphology and were predominantly within the size 
range of 4-20 nm. The X-ray diffraction pattern showed 
pure CeO2NPs with the typical peak broadening char-
acteristic of nanosized particles. Initially, the employed 
NPs are positively charged, and the colloidal stability 
is mediated by electrostatic repulsion (zeta potential 
+43.0  ±  1.3  mV, conductivity 0.303  ±  0.006  mS/cm, 
and pH 4.3). Albumin conjugation in the surface of 
the CeO2NPs has been characterized by the increase 
in dynamic light scattering (from 5 to 20  nm) and 
decrease in zeta potential (from +42.8 to −10  mV, 
which is the average zeta potential value of proteins in 
serum) (Supporting Fig. S1). Indeed, the solubility of 
CeO2NPs in physiological media is challenging, and 
a strong tendency to aggregate and sediment impedes 
their medical use even more, modifying their protec-
tive effects toward the proinflammatory (https://www.
front iersin.org/artic les/10.3389/fimmu.2017.00970/ 
full). To evaluate the electronic structure of the 
CeO2NPs and the influence on Ce valence state due 
to the presence of rat serum albumin, we performed 
X-ray photoelectron spectroscopy measurements. Ce 
three-dimensional spectra of all samples are shown in 
Supporting Fig. S2, where it can be clearly observed 
that the Ce3+/Ce4+ ratio is not affected by the presence 
of bovine serum albumin in the CeO2NPs surface.
tHe Rat MoDel oF  
DeN-INDUCeD lIVeR INJURy 
eXHIBItS CHaRaCteRIStICS  
oF MUltIFoCal HCC
Macroscopic examination of the liver specimens and 
histological examination confirmed the development of 
multifocal HCC nodules with a dysmorphic or dyschro-
mic appearance (Fig. 1A) that was markedly attenuated 
in the animals receiving CeO2NPs. Interestingly, DEN-
injured rats treated with CeO2NPs showed a signifi-
cantly lower liver/body weight ratio (Fig. 1B).
lIVeR aND SpleeN aRe tHe 
MaJoR taRgetS oF Ceo2Nps IN 
HCC RatS
Following intravenous CeO2NPs administration, tis-
sue Ce accumulation was analyzed by ICP-MS. Two 
weeks after the last administration of CeO2NPs 90.0% 
and 7.7% of the total dose of Ce collected was located 
in the liver and the spleen, respectively, whereas these 
figures were 77.3% and 21.7% 3 weeks after the com-
pletion of the CeO2NPs dosing schedule (Fig. 1C).
SeRUM BIoCHeMICal 
paRaMeteRS aND CIRCUlatINg 
leVelS oF alpHa-FetopRoteIN
HCC rats showed significant alterations of liver 
function tests such as decreased levels of albumin and 
glucose, higher levels of total bilirubin and total cho-
lesterol, and increased activity of markers of hepatocyte 
injury such as aspartate aminotransferase, alanine ami-
notransferase, and gamma-glutamyl transferase. We did 
not observe significant differences between HCC rats 
receiving or not receiving CeO2NPs (Supporting Table 
S2). However, nanoceria administration did significantly 
reduce the circulating levels of alpha-fetoprotein (AFP), 
a tumor-associated marker for HCC (Fig. 1B).
eFFeCt oF Ceo2Nps oN 
CollageN CoNteNt aND 
CellUlaR apoptoSIS IN lIVeR 
tISSUe
Long-term administration of DEN promoted 
incipient formation of fibrotic septa and periportal 
accumulation of collagen as a consequence of continu-
ous hepatic injury. However, no significant differences 
in hepatic collagen content were noted between treated 
and nontreated rats with HCC (Fig. 2A).
The terminal deoxynucleotidyl transferase–mediated 
deoxyuridine triphosphate nick-end labeling (TUNEL) 
assay showed a significant increase in positive cells in the 
liver sections of DEN-injured rats treated with CeO2NPs 
(Fig. 2B). We also observed a significantly increased 
protein expression of activated caspase-3 in HCC rats 
treated with CeO2NPs (Fig. 2C). These results indicate 
that treatment with CeO2NPs results in acceleration of 
apoptosis, thereby inhibiting HCC growth.
Ceo2Nps DeCReaSe 
MaCRopHage INFIltRatIoN 
aND ReDUCe INFlaMMatoRy 
geNe oVeReXpReSSIoN IN lIVeR 
tISSUe
Macrophage infiltration measured by positive 
cluster of differentiation 68 (CD68) staining was 
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observed in intratumoral and peritumoral areas, 
being significantly lower in HCC rats receiving 
CeO2NPs (Fig. 3A). mRNA expression of inflam-
matory, macrophage phenotype, cell growth and 
differentiation genes was analyzed in liver biopsies 
of control and HCC rats. Chronic administration 
of DEN induced higher gene expression of mac-
rophage M1 markers, such as interleukin 1 beta, 
tumor necrosis factor alpha, inducible nitric oxide 
synthase, and cyclooxygenase-2 (Supporting Table 
S3). Interestingly, administration of CeO2NPs sig-
nificantly down-regulated M1 genes involved in 
proinflammatory function.
Ceo2Nps DeCReaSe HepatIC 
CellUlaR pRolIFeRatIoN
We assessed the effect of CeO2NPs on cell pro-
liferation and the phosphorylation levels of proteins 
involved in tumor progression. Immunohistochemistry 
revealed abundant cellular proliferation in liver sec-
tions from DEN-injured animals. The cell prolifer-
ation rate, measured as the percent of Ki67-positive 
hepatocyte nuclei, was markedly lower in CeO2NPs-
treated rats (Fig. 3B). To ascertain the potential effect 
of CeO2NPs on interfering with the Ras/mitogen- 
activated protein kinase (MAPK) signaling pathway, 
FIg. 1. DEN-induced model of HCC and biodistribution of CeO2NPs. (A) Representative photographs of the liver and hematoxylin and 
eosin staining (magnification, 40) from control and DEN-injured rats. DEN was administered for 16 weeks, followed by a 2-week washout 
period. Green arrows point at nodules present in HCC rats. (B) Body weight, liver/body weight ratio, and serum levels of AFP in control 
rats and HCC rats. Serum samples were collected 1 week after the last dose of CeO2NPs. (C) ICP-MS quantification of cerium. Major 
organs and serum from HCC rats receiving CeO2NPs collected at two different time points: 2 (n = 3) and 3 (n = 4) weeks after the last 
administration of CeO2NPs. This corresponds to the nineteenth and twentieth weeks after starting DEN administration. **P < 0.01 and 
***P < 0.001 versus control; #P < 0.05 versus HCC + vehicle. One-way analysis of variance and Newman-Keuls post hoc test.
CA
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we assessed protein expression of total extracellular 
signal–regulated kinase 1/2 (ERK1/2) and phosphor-
ylated ERK1/2 (P-ERK1/2) in liver samples of HCC 
rats by western blot. It was of note that CeO2NPs 
treatment resulted in a significant reduction of 
P-ERK1/2 (Fig. 3C). These results suggest that the 
antiproliferative action of CeO2NPs is related to 
interference with the Ras/MAPK signaling pathway 
in HCC rats.
eFFeCt oF Ceo2Nps oN alteReD 
Cell SIgNalINg patHWayS IN 
lIVeR tISSUe
To investigate the effects of CeO2NPs on 
kinase-driven signaling pathways, we evaluated the 
phosphoproteome profile by mass spectrometry 
(MS). We identified and quantified a total of 5,048 
phosphopeptides in six independent biological rep-
licates that were run twice. Principal component 
analysis showed that CeO2NPs-treated samples sep-
arate from vehicle-treated samples in principal com-
ponent 1 (Fig. 4A). At arbitrary threshold values of 
±0.8-fold change (log2) and P  ˂  0.05, the phos-
phorylation of 349 peptides was increased, while 
the phosphorylation of 133 was decreased after 
CeO2NPs treatment (Fig. 4B; Supporting Table S4). 
This set of regulated phosphopeptides included 20 
phosphorylation sites in kinases, of which 11 were 
increased and nine were decreased (Fig. 4C). Gene 
ontology analysis showed that cell–cell adhesion 
and RNA splicing were enriched in the set of genes 
FIg. 2. Effect of CeO2NPs on hepatic fibrosis and cellular apoptosis. (A) Sirius red staining of representative liver sections obtained 
from control and DEN-injured rats (magnification, 100). (B) Representative TUNEL assay in liver sections of control rats and HCC rats 
(magnification, 200). White arrows point to apoptotic (red) cells. (C) Representative western blot for activated caspase-3 in liver tissue 
of control rats and HCC rats. *P < 0.05 and ***P < 0.001 versus control group; #P < 0.05 and ##P < 0.01 versus HCC + vehicle. One-way 
analysis of variance and Newman-Keuls post hoc test, Kruskal-Wallis test, and Dunn’s post hoc test, with unpaired Student t test when 
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that code for the regulated phosphopeptides (Fig. 
4D). The set of regulated phosphopeptides linked 
to cell–cell adhesion included 43 sites in 27 proteins 
that presented an increased phosphorylation after 
CeO2NPs treatment and 16 sites in 11 proteins that 
presented a decreased phosphorylation after NP 
treatment (Fig. 4E). In addition, proteins linked to 
cell-matrix adhesion including CD44 and integrin 
beta 4 (Itgb4) showed a decreased phosphorylation 
after CeO2NPs treatment (Fig. 4F). Finally, the set 
of regulated phosphopeptides linked to RNA splic-
ing included 36 sites in 18 proteins that presented 
increased phosphorylation and four sites in three 
proteins that showed decreased phosphorylation 
(Fig. 4G). These data suggest that CeO2NPs have a 
global effect on the phosphorylation pattern of liver 
cells from rats with HCC that mainly affects pro-
teins related to cell adhesion and RNA splicing.
FIg. 3. Effect of CeO2NPs on infiltrating cells, cellular proliferation, and levels of P-ERK1/2 in tumoral tissue. (A) CD68 immunostaining 
of representative liver sections from HCC rats (magnification, 200). (B) Ki67 immunostaining of representative liver sections from HCC 
rats (magnification, 200). Red arrows mark nuclei positive for Ki67 staining. (C) Representative western blots of total ERK1/2 and 
P-ERK1/2 in liver homogenates of control rats and HCC rats. Forty micrograms of protein extracts were loaded per lane. *P < 0.05 and 
**P < 0.01 versus control; ##P < 0.01 versus HCC + vehicle. One-way analysis of variance and Newman-Keuls post hoc test, with unpaired 
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eFFeCt oF Ceo2Nps oN HepatIC 
lIpID MetaBolISM
Analysis of total fatty acids (FAs) of principal lipid 
components in hepatic tissue of HCC animals indi-
cates a dysregulation of FA metabolism mainly occur-
ring in cholesterol ester (CE)– and nonesterified FA 
(NEFA)– derived FAs (Supporting Table S5). The most 
important effects induced by CeO2NPs were found in 
phosphatidylcholine (PC)–derived FAs, which are by far 
the most abundant lipid component in the liver. In fact, 
we observed a significant decrease in polyunsaturated 
FAs (PUFAs), which was exclusively due to a marked 
diminution in arachidonic acid (AA; C20:4n6; Fig. 5A). 
We also observed significant changes in C14:0, C16:1, 
and C17:0, although the differences were quantitatively 
much less important. Moreover, in NEFA-derived, 
triglyceride (TG)-derived, and CE-derived FAs, we 
FIg. 4. Effect of CeO2NPs on the phosphoproteome of livers from rats with HCC. (A) Principal component analysis showing the global 
effect of CeO2NPs on the phosphoproteome of hepatic cells from HCC rats. Blue dots (VH) indicate biological replicates treated with 
vehicle, while red dots (NP) indicate replicates treated with CeO2NPs. (B) Volcano plot showing phosphopeptides regulated by CeO2NPs. 
Peptides were considered regulated when P < 0.05 (1.3 in –log10 scale) and fold change in log2 scale >0.8 (increased) or <−0.8 (decreased). 
Statistical significance was assessed using an unpaired two-tailed Student t test. (C) Chart showing phosphorylation sites in kinases 
regulated by CeO2NPs treatment. (D) Volcano plot showing gene ontologies enriched in proteins whose phosphorylation was regulated by 
CeO2NPs. Statistical significance of the enrichment was assessed using a modified Fisher’s exact test. (E) Phosphorylation sites linked to 
cell–cell adhesion and regulated by CeO2NPs treatment. (F) Effect of CeO2NPs treatment over the phosphorylation of CD44 and Itgb4. 
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observed that HCC rats showed significantly increased 
liver content of linoleic acid (LA; C18:2n6) than 
healthy rats, a phenomenon that was reversed in HCC 
animals treated with CeO2NPs (Fig. 5B). Of note, on 
analyzing phosphatidylethanolamine (PE)–derived FAs, 
we observed that CeO2NPs administration was associ-
ated with a significant reduction in the very long chain 
PUFA docosahexaenoic acid (C22:6n3) (Fig. 5C).
Ceo2Nps IMpRoVe SURVIVal IN 
DeN-INJUReD RatS
To assess how the above changes translate into 
clinical outcome, we investigated the impact of these 
NPs on the survival of two groups of HCC rats. The 
median survival reached by CeO2NPs-treated rats was 
significantly higher than that in rats receiving vehicle 
(P < 0.05) (Fig. 6A). Next, we were interested in com-
paring the effect of CeO2NPs to that of sorafenib. Four 
groups of rats receiving vehicle, CeO2NPs, sorafenib, 
and CeO2NPs plus sorafenib were investigated. The 
median survival was markedly lower in HCC rats 
receiving vehicle (15.5  days, P  <  0.05) than in those 
animals receiving CeO2NPs (31  days), sorafenib 
(33.5  days), or CeO2NPs plus sorafenib (33.5  days) 
(Fig. 6B). The combined therapy showed the longest 
survival, although differences did not reach statistical 
significance.
FIg. 5. Representative chromatogram of PC-derived FAs in rats with HCC. (A) Superposition of a representative gas chromatography MS 
total ion current chromatograms showing the analysis of PC-derived FAs obtained from HCC rats treated with vehicle (red) or CeO2NPs 
(blue). The represented peaks are the FAs which showed significant differences between groups. Gas chromatography peaks are labeled with 
the corresponding FA identification. For each peak there is a graph with the quantification of the FA. (B) Effect of nanoceria treatment in 
linoleic FAs in different lipid components (NEFA, TG, and CE). (C) Effect of CeO2NPs in PE-derived docosahexaenoic acid (C22:6n3). 
*P < 0.05 and **P < 0.01 versus control; #P < 0.05 versus HCC + vehicle. Unpaired Student t test and Mann-Whitney test when appropriate.
A
B C
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Ceo2Nps ReteNtIoN By HUMaN 
lIVeR
To determine whether CeO2NPs can be internal-
ized by the human liver, three experimentally viable 
human livers, declined for transplantation, were per-
fused with CeO2NPs under normothermic machine 
perfusion (NMP) (Supporting Information). Liver 
function tests and hemodynamic parameters were 
monitored during perfusion (data not shown) to 
ensure organ viability and proper device functioning.
To study the cellular uptake and intracellular local-
ization of CeO2NPs in human livers, ICP-MS and 
TEM imaging were performed. The concentration of 
Ce in the serum leaving the liver through the hepatic 
veins reached the highest levels 15 minutes after NPs 
administration (Fig. 7A). At 30 minutes of perfusion, 
the amount of Ce in the perfusate was reduced by at 
least 50% when compared to the previous time point 
and further decreased at 60  minutes. In the case of 
donor H3, at 60 minutes of NMP, the Ce concentra-
tion in the perfusate was still around 45% due to the 
fact that in this particular organ the injected dose of 
NPs was almost 100 times higher than in H1 and H2 
livers.
Ce subcellular location was examined using con-
ventional bright and enhanced dark field TEM. Liver 
tissue from all donors was morphologically well pre-
served, and the cells presented a viable morphology. 
Liver biopsies obtained from donor H3 were exam-
ined under conventional TEM and energy-dispersive 
X-ray spectroscopy (EDX). In conventional TEM, 
CeO2NPs appeared as small, dense, black structures 
in the form of agglomerates of different sizes inside 
blood vessels, the space of Disse, endothelial cells, 
and some blood circulating cells (Fig. 7B). CeO2NPs 
FIg. 6. Effect of CeO2NPs on survival. (A) HCC rats randomly received two weekly doses of CeO2NPs or vehicle through the tail vein at 
the sixteenth and seventeenth weeks, and their survival was analyzed. (B) HCC rats were randomly distributed into four groups receiving 
vehicle, CeO2NPs, sorafenib, or the combination CeO2NPs and sorafenib. Sorafenib was delivered daily by intragastric administration 
(10 mg/kg) for 14 days. P < 0.05 and P < 0.01 versus HCC + vehicle, log-rank (Mantel-Cox) test.
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were observed both free and within intracellular, sin-
gle-membrane, endosome-like organelles. In dark 
field TEM, given its high atomic number relative to 
the elements typically found in organic tissues, Ce is 
expected to appear as very bright dots, as shown in 
Fig. 7B. The presence of Ce was further confirmed 
using high-angle annular dark-field scanning trans-
mission electron microscopy (HAADF-STEM), 
which provides structural and chemical information 
with atomic resolution. Figure 7C shows a representa-
tive region in the set of analyzed images. The elemen-
tal map (central panel) shows the spatial distribution 
of Ce in the region outlined in the left panel, and the 
EDX spectrum (right panel) confirms the elemental 
composition. In addition to Os from the postfixation, 
Cu from the TEM grid, and Pb from the staining, Ce 
is the only element detected by using EDX analysis.
Ceo2Nps aDSoRptIoN By  
HUMaN HepatoCyte CaNCeR 
CellS
To assess whether human hepatocytes can inter-
nalize CeO2NPs, HepG2 cells, a human derived cell 
cancer line, were exposed to CeO2NPs (10  µg/mL) 
for 24 hours and subjected to TEM analysis. NPs were 
FIg. 7. Accumulation of Ce in isolated human livers. (A) Amount of Ce in the perfusate 0, 15, 30, and 60 minutes after NP administration. 
ICP-MS data are expressed as percent of Ce present in the perfusate compared to the highest Ce amount present in the serum of each 
liver. (B) Assessment of CeO2NPs subcellular location in human hepatic tissue after 1 hour of NP infusion; (1,2,3) TEM image of a blood 
vessel containing NPs surrounded by hepatocytes. In bright field (1), aggregates of CeO2NPs (white arrows) appear as dark, electrodense 
spots. In dark field (2), nanoparticles are seen bright. (3) Magnified view of the boxed area depicting the nanoparticles in the space of 
Disse. (4,5) TEM image of a hepatocyte in the proximity of an endothelial cell containing CeO2NPs, bright and dark field, respectively. 
(6) High-magnification micrograph of the boxed area showing in detail the NPs inside the endothelial cell. *Apoptotic cell. (C) (1) 
STEM-HAADF image of endosome-like vesicles of an endothelial cell. (2) STEM-EDX element-distribution map showing the spatial 
distribution of Ce in the region outlined. Four adjacent pixel/spectra binned for each point. (3) EDX sum spectrum (Y = counts, X = keV) 
showing the average elemental composition of the image. Abbreviations: E, endothelial cell; ER, endoplasmic reticulum; H, hepatocyte; 
LD, lipid droplet; M, mitochondria; N, nucleus; P, platelet; RBC, red blood cell; S, sinusoid; SD, space of Disse.
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strongly attached to the outer leaflet of the plasmatic 
membrane, free in the cytoplasm, and mostly inside 
numerous endosome-like bodies of diverse morphology 
(Fig. 8A). The mitochondria, the endoplasmic retic-
ulum, and the nucleus of these hepatocytes appeared 
normal. To verify that the electron-dense granules were 
indeed CeO2NPs, we performed dark field microscopy 
followed by HAADF-STEM. In both dark field TEM 
and STEM, NPs appeared as bright spots. The Ce ele-
mental map and EDX spectrum confirmed the presence 
of Ce in the preparations (Fig. 8B).
Discussion
The ability of nanoceria to catalyze redox reac-
tions has been widely used in petrochemical 
industries and catalytic exhaust converters for 
decades.(33) The use of these NPs as a therapeutic 
tool is still a matter of concern. This is mainly due 
to the tendency of CeO2NPs to evolve when in con-
tact with physiological media.(34) Variability in the 
response and loss of antioxidant activity are the out-
comes of these alterations. In the current investiga-
tion, some of these difficulties have been overcome 
by preparing albumin-coated CeO2NPs with high 
monodispersity and high stability in the physiologi-
cal media. This coating prevents the development of 
large NP aggregates and protein corona formation, 
resulting in a stable colloidal solution with sustained 
and more intense effects.
Unfortunately, HCC is still rather orphan in terms 
of highly effective systemic treatment. In this con-
text, oxidative stress, mainly contributed by ROS, has 
FIg. 8. CeO2NPs adsorption in human hepatocyte cancer cells. (A) TEMs of HepG2 cells showing the uptake of NPs: (1) hepatocyte 
exposed to CeO2NPs (white arrows) for 24 hours, with some NPs adhering to the cell membrane, others confined to vesicles, and a few 
free in the cytoplasm; (2) formation of pseudopodia with NPs in the center; (3,4) vesicle loaded with CeO2NPs in bright and dark fields, 
respectively. (B) (1) TEM image displaying NPs in the cytoplasm of a hepatocyte; (2) STEM-HAADF image from the NPs; (3) Ce 
elemental mapping with four adjacent pixel/spectra binned for each point; (4) EDX sum spectrum (Y = counts, X = keV) showing the 
average elemental composition of the image. Abbreviations: ER, endoplasmic reticulum; LD, lipid droplet; M, mitochondria; N, nucleus.
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been implicated in the pathogenesis of several diseases 
including cancer. It is well known that ROS can drive 
the initial development and progression of cancer as 
well as down-regulate antioxidant enzymes that nor-
mally combat free radical production.(10) Consequently, 
many antioxidant compounds, enzymes, and inhib-
itors of reduced nicotinamide adenine dinucleotide 
phosphate oxidase have been studied for treating 
chronic inflammation and cancer. However, results to 
date have been suboptimal, mainly due to their low 
systemic bioavailability and insufficient levels at the 
target sites.
Here we consider that CeO2NPs could be an 
NP-based therapy platform in HCC, which would be 
able to induce ROS degradation and tumor recession 
by virtue of their great self-regenerating antioxidant 
capacity. Because the antioxidant effect of CeO2NPs 
is catalytic and consequently permanent, this would 
represent a clear competitive advantage over other 
antioxidant therapies needing permanent application. 
In addition, CeO2NPs are only active as a catalyst 
when there is an excess of ROS; otherwise, they are 
inert and appear innocuous.
The carcinogenic effect of DEN is due to an 
enhancement of hepatocyte proliferation mainly 
in the centrilobular hepatocytes. DEN is bioacti-
vated following hydroxylation by the cytochrome 
P450 (CYP) system; then, the hydroxylated DEN 
is oxidized by CYP2E1 to reactive products in rat 
liver liposomes. DEN-treated rats displayed macro-
scopically distorted liver, with altered liver weight 
and anomalous microscopic architecture of the liver 
parenchyma showing diffuse dysplasia and fibrotic 
tracts. This prompted us to assess whether the HCC 
liver, as indeed occurs in the normal liver, is also a 
main target for CeO2NPs. Our results further con-
firm that, even in a liver with intense tumorigenic 
activity, CeO2NPs maintain their high selective tar-
geting on the hepatic tissue.
Parameters indicating altered tissue growth or 
proliferation and ongoing proinflammatory pro-
cesses were significantly less activated in rats receiv-
ing CeO2NPs. Treated rats showed increased liver/
body weight ratio, decreased macrophage infiltration, 
and lower amount of Ki67-positive cells. Ki67 is a 
nuclear antigen extensively used as a proliferation 
marker and as a prognostic indicator for cancer. We 
also observed decreased serum concentration of AFP, 
the main serological biomarker of dedifferentiation 
of hepatocytes that is associated with the devel-
opment of HCC. This occurred in the frame of 
attenuated macrophage M1 proinflammatory gene 
expression in the liver tissue of HCC-treated rats. 
Tumor-associated macrophages are well known for 
their trophic abilities and for providing immuno-
suppressive tumor microenvironment and therefore 
facilitating tumor progression.(35) In that sense, low-
ering macrophage numbers in liver tissue by means 
of chemotaxis inhibition or cell death could partially 
explain the antitumor effects of nanoceria.
Evidence supports that CeO2NPs have a specific 
antitumorigenic effect in HCC rats. First, following 
NPs administration, we observed increased liver apop-
totic activity. This is consistent with previous studies 
describing that after exposure to antioxidant cuprous 
oxide NPs, lung melanoma cells activate caspase-3 and 
caspase-9, inducing apoptosis of tumor cells.(36) On the 
other hand, CeO2NPs also resulted in decreased levels 
of P-ERK1/2, an essential component of the Ras/Raf/
MAPK kinase/ERK signaling pathway. This is among 
the principal routes controlling cell survival, differen-
tiation, proliferation, growth, angiogenesis, regulation 
of glucose and lipid metabolism, and inflammation.(37) 
The impact of CeO2NPs on cell phosphorylation 
in HCC has not been systematically investigated 
using untargeted MS-based proteomics. Our initial 
principal component analysis suggests a global effect 
of CeO2NPs over protein phosphorylation in the liver 
of HCC rats that significantly affected 9.5% of all 
detected phosphorylation sites. The effect of CeO2NPs 
comprised both increased and decreased phosphoryla-
tion. The administration of CeO2NPs affected kinases 
involved in signaling pathways related to apoptosis, 
cell proliferation, migration, and survival such as p21 
(RAC1) activated kinase 2, eukaryotic elongation fac-
tor 2 kinase, protein tyrosine kinase 2/focal adhesion 
kinase 2, and NIMA-related kinase 9. Interestingly, 
a gene ontology analysis showed an enrichment of 
proteins linked to RNA splicing and cell–cell adhe-
sion in the subset of proteins whose phosphorylation 
were significantly regulated after CeO2NPs treatment. 
Splicing is a process frequently deregulated in can-
cer cells because it can regulate the function of key 
proteins involved in apoptosis, proliferation, angio-
genesis, and migration.(38) In this regard, CeO2NPs 
treatment that reduced cell proliferation caused both 
an increase and a decrease in the phosphorylation of 
proteins involved in splicing. Cell adhesion is also a 
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process heavily deregulated in cancer cells with mul-
tiple proteins involved in cell–cell adhesion consid-
ered as tumor suppression or oncogenes.(39) Our gene 
ontology analysis indicates that CeO2NPs produce a 
large effect on the phosphorylation pattern of proteins 
involved in cell–cell adhesion with proteins presenting 
both overphosphorylation and downphosphorylation, 
suggesting an alteration in this biological process. We 
observed a reduced phosphorylation of two other cell 
surface proteins involved in cell adhesion, CD44 and 
Itgb4.
A hallmark of cancer cells is dysregulation of FA 
metabolism to support proliferation.(40) Accordingly, 
total serum TG and cholesterol were found to be sig-
nificantly decreased in HCC rats. Highly proliferative 
cancer cells have strong lipid and cholesterol avidity; 
consequently, these cells either increase the uptake 
of exogenous lipids or overactivate their endogenous 
synthesis.(41) Excessive lipids and cholesterol in cancer 
cells are stored in lipid droplets as cholesteryl esters,(37) 
which is in agreement with our findings of increased 
CE-derived FAs in hepatic HCC tissue. The analysis 
of principal lipid components also revealed an increase 
in NEFA probably due to an increased generation to 
support tumor growth.
The most important effects induced by CeO2NPs 
are found in PC-derived FAs. The decrease in 
PC-PUFAs resulting from CeO2NPs administration 
was mostly due to a decrease in AA.(42) Phospholipases 
A2, C, and D can mediate the release of esterified AA 
from cellular phospholipids, a process which already 
seems incremented in HCC. Free AA can be metab-
olized through enzymatic reactions or act as a second 
messenger in signal transduction pathways(43); some 
of these pathways were demonstrated to be signifi-
cantly up-regulated in our HCC rats. After nanoceria 
treatment, the decrease in esterified PC-AA was more 
pronounced. This phenomenon seems to be related to 
the increase of apoptosis in these rats because free AA 
is able to promote the activation of sphingomyelinase 
and the apoptotic process.(44)
CeO2NPs treatment reversed the increase in 
NEFA-derived, TG-derived, and CE-derived LA in 
HCC rats. LA, one of the most abundant FAs in all 
lipid components, has been reported to change the 
metabolism of intrahepatic CD4+ T cells, leading 
them to apoptosis and, thus, contributing to HCC 
development.(44) Neoplastic hepatocyte lesions have 
been associated with changes in the PUFA profile, 
which are likely due to an abnormal essential FA 
metabolism involving Δ-6 desaturase (Δ-6D).(43) The 
activity and expression of this desaturase are regulated 
by the intracellular redox state.(45) This suggests that 
the restoration of normal hepatic levels of LA in the 
HCC rats treated with CeO2NPs could result from 
the reactivation of Δ-6D activity due to the reduction 
in oxidative stress.
The translation of the antitumorigenic effects 
induced by CeO2NPs into a clinically significant 
improvement was assessed by investigating the 
effect of CeO2NPs on survival. Treated HCC rats 
showed a clear amelioration in this parameter. To 
date, tyrosine kinase inhibitors, such as sorafenib, 
lenvatinib, cabozatinib, or regorafenib, as well as the 
antiangiogenic antibody ramucirumab, are consid-
ered effective therapies in patients with advanced 
HCC.(46) The effect of CeO2NPs on overall survival 
was similar to that observed with sorafenib, which 
indicates that these NPs are at least as effective as 
sorafenib under the conditions studied. The com-
bination of both treatments did not result in an 
additional improvement in survival in comparison 
to each treatment administered alone. CeO2NPs 
and sorafenib likely interfere with common signal-
ing pathways, such as angiogenesis through vascular 
endothelial growth factor signaling, which would 
explain why the combination of both compounds 
did not result in any additional effect. The effects 
of CeO2NPs on the ERK1/2 signaling pathway, the 
modulation of the phosphorylation state of a high 
number of peptides, and their manifestations on cell 
proliferation and apoptosis mirror some the abun-
dant data reported on sorafenib effects.(47)
For a comprehensive understanding of whether 
the behavior of CeO2NPs in the human liver resem-
bles that observed in rats with HCC, we admin-
istered nanoceria to human livers under ex vivo 
normothermic perfusion. The ex vivo experiments 
confirmed that CeO2NPs have high avidity for 
human liver because they accumulate in the target 
tissue readily after administration. The NPs were 
found both free and within intracellular, single- 
membrane, endosome-like organelles. The elemen-
tal analysis combined with the STEM helped us to 
confirm their presence and distinguish them from 
endogenous structures and artifacts in the tissue. 
Moreover, in vitro experiments with the HepG2 
cell line confirmed the uptake and retention of 
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CeO2NPs by human hepatocyte cancer cells mostly 
in endosome-like bodies.
In conclusion, these results indicate that the anti-
oxidant properties of CeO2NPs partially revert cell 
mechanisms involved in tumor progression and sig-
nificantly increase survival in HCC rats, indicating 
that this inorganic nanomaterial represents an effec-
tive treatment in experimental HCC. These findings 
suggest that CeO2NPs alone or in combination with 
the current molecular targeted therapies could be 
effective at stopping or attenuating the tumoral pro-
gression in patients with HCC.
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